However, the dosage and optimal duration of therapy with the use of recombinant tissue plasminogen activator (r-tPA) as a thrombolytic agent are not well-studied in children.12, 13There is a well-documented increased risk of intraventricular hemorrhage (IVH) and other sequelae for thrombolysis treatment in infants, creating uncertainty and hesitancy surrounding treatment options.14 The gene discussed is PLAT; the disease is Intraventricular hemorrhage.